Expanded collaboration will investigate health interventions using targets based on Viome's discovery platform that analyzes host & microbial interaction at the onset and progression of diseases

Published: Oct. 20, 2021 at 7:00 AM MDT

BELLEVUE, Wash., Oct. 20, 2021 /PRNewswire/ --Viome Life Sciences, a mission-driven systems biology company aiming to help individuals improve their health, today announced the expansion of itstwo-year partnership with GSK, a science-led global healthcare company, to expand clinical research activities1 and potential development of new therapeutic interventions within the fields of chronic diseases including autoimmune diseases and cancers. This expansion builds on a previously announced collaboration to research the prevention of specific chronic diseases, leveraging Viome's proprietary microbiome analysis and artificial intelligence platforms and GSK's expertise in immunology.

"Most chronic disorders are treated with drugs targeting symptoms and not causes. Viome's unique mRNA technology and state-of-the-art artificial intelligence platform have the potential to find the root causes of specific chronic disorders and cancers. With that critical information and the unique expertise of GSK, we aspire to one day cure these diseases and not just manage the symptoms," said Viome CEO and Founder, Naveen Jain. "We are excited to expand our collaboration with GSK to develop preventative and therapeutic measures for chronic diseases and cancers."

The gut microbiome is well recognized for its ability to shape immune fitness, with nearly 70-80% of the immune system housed inside the gut microbiome2 [PubMed]. A healthy gut microbiome supports the immune system, which is connected to an individual's overall well-being, weight, energy, mood, and stress. Imbalances in the gut microbiome have been associated with inflammation and chronic diseases ranging from gastrointestinal inflammatory and metabolic conditions to neurological, cardiovascular, and respiratory illnesses3[NCBI].Through this collaboration, Viome and GSK will examine the connection between the gut microbiome and specific chronic disorders by performing a clinical validation trial. The overall objective of the collaboration aims to advance viable health interventions for the many diseases that continue to threaten individuals, families, and communities around the world.

"A better understanding of the interactions between the immune system and microbiome which have been shown to have a significant impact on human health has been part of GSK's innovation strategy," said Rino Rappuoli, Head of R&D Vaccines, GSK. "By combining our robust expertise in immunology with Viome's unique technology with its proprietary mRNA analysis and artificial intelligence platform, we look forward to uncovering additional key insights into chronic diseases."

Through this partnership, GSK and Viome will continue to examine chronic diseases that are without treatment and will work to develop much-needed new targets for potential interventions. GSK and Viome understand the potential of the gut microbiome to influence an individual's immune system and determine the effectiveness of health interventions and will tap into Viome's extensive research and findings as well as GSK's expertise to accomplish this. Viome is committed to creating a world where chronic diseases could truly be prevented before they cause significant problems.

About Viome Life SciencesViome Life Sciences is a mission-driven systems biology company founded in 2016 totackle the epidemic of chronic diseases, cancer, and aging. To help individuals improve their health and to better understand the root of chronic diseases, Viome is strategically split into two divisions. Viome Consumer Services is focused on growing its established consumer products including tests, nutrition plans, and supplements. Viome Health Sciences is devoted to advancing its precision diagnostics and therapeutics platform. By conducting mRNA analysis at a mass scale, Viome is digitizing human biology and ultimately stopping the onset and progression of chronic diseases. Recently, Viome garnered FDA Approval for its unique mRNA technology and AI platform to detect cancers and has already successfully developed over 30 predictive models for some of the most prominent chronic diseases. For further information please visit http://www.viome.com/company

About GSKGSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit http://www.gsk.com/en-gb/about-us.

Media ContactKendall Donohueviome@factorypr.com

1Viome Press release, Viome announces scientific collaboration with GSK to research the prevention of specific chronic diseases, 14 November 2019 available at: Viome announces scientific collaboration with GSK to (globenewswire.com)2G. Vighi et al, "Allergy and the gastrointestinal system" in Clin Exp Immunol. 2008 Sep; 153(Suppl 1): 36.3Juliana Durack and Susan V. Lynch, "The gut microbiome: Relationships with disease and opportunities for therapy" in J Exp Med. 2019 Jan 7; 216(1): 2040.

View original content to download multimedia:

SOURCE Viome

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

See the original post:
Viome Life Sciences Announces Expansion of Collaboration with GSK into new therapeutic interventions for Cancers and Autoimmune Diseases - KKCO-TV